On October 18, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that it will feature new preclinical data on FPT155, its novel therapeutic CD80-Fc fusion protein, in a poster presentation at the 2017 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, Five Prime Therapeutics, OCT 18, 2017, View Source [SID1234521014]). The conference is scheduled to take place October 26-30, 2017, in Philadelphia, and abstracts may now be viewed online through the itinerary planner.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Know more, wherever you are:
Latest on AACR (Free AACR Whitepaper)-NCI-EORTC through 1stOncology, book your free 1stOncology demo here.
Abstract Number and Title: B005 – "FPT155, a novel therapeutic CD80-Fc fusion protein, with potent anti-tumor activity in preclinical models"
Session Title: Session PO.B01 – Immune Modulators
Session Date and Time: Sunday, October 29, 2017, 12:30 – 4:00 PM
Location: Hall E, Philadelphia Convention Center